trial

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCTId NCT01077700
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 214 (actual)
Sponsored by AbbVie
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
214 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-03
Primary completion
2011-07
Eligibility
ALL · 20 Years · 55 Years

Interventions & indications

Drugs
ABT-288 Low DoseABT-288 High Dose

Sponsors

AbbVieLead Sponsor

Investigators

1
George Haig, PharmDStudy Director

Sites

24 total
Anaheim, United StatesGarden Grove, United StatesNational City, United StatesNorwalk, United StatesPasadena, United StatesPico Rivera, United StatesRiverside, United StatesSan Diego, United StatesPlantation, United StatesChicago, United StatesShreveport, United StatesPittsfield, United States

Linked catalysts

1
Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizoph — primary completion2011-07

Facts & assertions

4 sourced
Enrollment
214
Phase
PHASE2
Primary Completion Date
2011-07
Status
COMPLETED
relationships
The graph out of here
drug
ABT-288 Low Dose
drug
ABT-288 High Dose
drug
lead_sponsor
AbbVie
company
indication
Cognitive Deficits in Schizophrenia
indication
investigator
George Haig, PharmD
person